| Neuromyelitis Optica
Enspryng vs Soliris
Side-by-side clinical, coverage, and cost comparison for neuromyelitis optica.Deep comparison between: Enspryng vs Soliris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliris has a higher rate of injection site reactions vs Enspryng based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliris but not Enspryng, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enspryng
Soliris
At A Glance
SC injection
Every 4 weeks
IL-6 receptor antagonist
IV infusion
Every 2 weeks
Complement C5 inhibitor
Indications
- Neuromyelitis Optica
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Neuromyelitis Optica Loading dose of 120 mg SC at Weeks 0, 2, and 4; maintenance dose of 120 mg every 4 weeks.
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Contraindications
- Known hypersensitivity to satralizumab or any inactive ingredient
- Active Hepatitis B infection
- Active or untreated latent tuberculosis
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=15%) nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, nausea
Serious infections, elevated liver enzymes, decreased neutrophil counts, hypersensitivity reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Pharmacology
IL-6 receptor antagonist; recombinant humanized anti-human IL-6 receptor monoclonal antibody that inhibits IL-6-mediated signaling by binding to soluble and membrane-bound IL-6 receptors.
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enspryng
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Enspryng
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Enspryng
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Neuromyelitis Optica Spectrum Disorder (NMOSD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Soliris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnspryngView full Enspryng profile
SolirisView full Soliris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.